Azelis reports sweetener issue and what it means for Azelis stock

Published on 10/06/2026 at 17:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Azelis reported EUR 2.2 billion first-half revenue, up 3.20 percent year over year. Azelis stock has a EUR 2.9 billion market value.

Azelis, BE0974400328, Illustration mit AI erstellt.

Azelis Group N.V. (ISIN BE0974400328) is addressing a New Zealand ingredient-labeling issue involving material sold as thaumatin. New Zealand Herald reported on October 6, 2026, that testing found the product supplied as thaumatin contained more than 99 percent sucralose. The company said the discrepancy was between the product ordered and the product received from its supplier.

Five batches shape the immediate risk

Azelis said analytical results covered five batches submitted for testing, while its New Zealand managing director said the company does not manufacture, repackage or relabel the material. The company also said it had informed New Zealand Food Safety and continued investigating the supplier chain, according to the New Zealand Herald.

The issue matters because distribution is central to Azelis's value proposition: customers rely on documentation, product specifications and quality controls when sourcing specialized ingredients. The report said the matter was treated as a labeling issue rather than a public health risk, while New Zealand authorities continued their investigation.

Revenue growth returns in 2026

The latest reported operating figures provide a broader counterweight. In the first half of 2026, revenue reached EUR 2.2 billion, up 3.20 percent year over year in constant currency, according to the Yahoo Finance transcript of the July 30, 2026 earnings call.

Gross profit rose 4.30 percent to EUR 524.0 million, lifting the gross margin to 24.20 percent. Adjusted EBITDA increased 2.60 percent to EUR 233.0 million, while operating profit fell to EUR 188.0 million from EUR 191.0 million in the first half of 2025. The mix shows improving gross economics alongside continued pressure below the operating line.

Cash generation reached EUR 122.0 million in the first half, but free cash flow conversion declined to 52.30 percent from 63.80 percent. Net debt stood at EUR 1.6 billion and leverage was 3.4 times at the end of June 2026, leaving balance-sheet execution as an important part of the investment case.

Market value and yearly range

Azelis had a market capitalization of EUR 2.9 billion as of October 6, 2026. Its 52-week range was EUR 6.88 to EUR 12.58, giving the supply-chain issue a market context shaped by a broad yearly trading band rather than a single short-term level.

On the Brussels listing, Azelis is classified in the industrials sector and distributes specialty chemicals and food ingredients across life sciences and industrial markets. The company profile identifies personal care, pharmaceuticals, food, agriculture, coatings, adhesives and electronics among its end markets.

What the issue means for Azelis

The immediate test is whether the New Zealand matter remains isolated to the five tested batches or expands into a wider supplier-control question. The first-half figures show that Azelis returned to growth, but the EUR 1.6 billion net debt balance and the 52.30 percent cash-conversion rate make operational discipline financially relevant. Investors weighing Azelis stock therefore have two dated reference points: a 3.20 percent revenue increase in the first half of 2026 and a fresh product-quality investigation reported on October 6, 2026.